---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-006408"
form_type: "8-K"
ticker: "VNOV"
cik: "0001699709"
company_name: "VitaNova Life Sciences Corp"
filed_at: "2023-09-14T23:59:59+00:00"
generated_at: "2026-06-10T17:41:49.797569+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Yijia Group founder/CEO Xianchang Ma dies; heir gets 86.3% control; new CEO appointed

## Summary
- Founder and sole director Xianchang Ma passed away on August 3, 2023.
- On Sept 12, 2023, heir Caihong Qu acquired 5,066,250 shares (86.3% of outstanding) at $0 consideration, gaining control.
- Effective Sept 13, 2023, board comprises Qiuping Lu and Ruiming Zhou; Lu appointed CEO, President, and CFO.
- Ms. Lu previously served as CEO and CFO of China Herb Group Holdings from 2014 to 2019.
- Mr. Zhou has been a director at Shandong Tengjunxiang Biotechnology Co. since June 2017.

## SEC filing metadata
- accession: 0001683168-23-006408
- form_type: 8-K
- ticker: VNOV
- cik: 0001699709
- company_name: VitaNova Life Sciences Corp
- filed_at: 2023-09-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/yijia_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-006408
- JSON: https://secwatch.observer/filing/0001683168-23-006408.json
- Plain text: https://secwatch.observer/filing/0001683168-23-006408.txt

## Key facts
- Executive change
  Xianchang Ma departed as Chief Executive Officer, President, Chief Financial Officer and Director at VitaNova Life Sciences Corp.
  - Action: passed away
  - Role: Chief Executive Officer, President, Chief Financial Officer and Director
  source text: Mr. Xianchang Ma, previously the Chief Executive Officer, President, Chief Financial Officer and Director of the Company, passed away on August 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm
- Executive change
  Qiuping Lu was appointed as Chief Executive Officer, President, Chief Financial Officer at VitaNova Life Sciences Corp.
  - Action: appointed
  - Role: Chief Executive Officer, President, Chief Financial Officer
  source text: On September 13, 2023, the Board resolved to appoint Ms. Qiuping Lu as the Chief Executive Officer, President, Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm
- Executive change
  Ruiming Zhou was appointed as Director at VitaNova Life Sciences Corp.
  - Action: inducted
  - Role: Director
  source text: On September 13, 2023, the majority shareholder inducted Ms. Qiuping Lu, and Mr. Ruiming Zhou to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm
- Executive change
  Qiuping Lu was appointed as Director at VitaNova Life Sciences Corp.
  - Action: inducted
  - Role: Director
  source text: On September 13, 2023, the majority shareholder inducted Ms. Qiuping Lu, and Mr. Ruiming Zhou to the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm
- M&A Transactions
  VitaNova Life Sciences Corp underwent a change of control involving Ms. Caihong Qu for $0 (closed 2023-09-12).
  - Action: change of control
  - Counterparty: Ms. Caihong Qu
  - Consideration: $0
  - Closing: 2023-09-12
  source text: Ms. Caihong Qu, Mr. Xianchang Ma's sole heir, was allocated 5,066,250 shares of the Company's common stock at a consideration of $0.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699709/000168316823006408/0001683168-23-006408-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.